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Introduction 
  The amphipathic helical peptide mastoparan (MP; 
H-INLKALAALAKKIL-NH2) inserts into biological 
membranes to modulate the activity of heterotrimeric G 
proteins and other targets.  Moreover, whilst cell free 
models of apoptosis demonstrate MP to facilitate 
mitochondrial permeability transition and release of 
apoptogenic cytochrome c, MP-induced death of intact 
cells has been attributed to its non-specific membrane 
destabilising properties (necrotic mechanisms).  However, 
MP and related peptides are known to activate other 
signalling systems, including p42/p44 MAP kinases [1] 
and could therefore, also modulate cell fate and specific 
apoptotic events.  
  The ability of MP to facilitate mitochondrial 
permeability in cell free systems has lead to proposals that 
MP could be of utility in tumour therapeutics provided that 
it conferred features of cellular penetration and 
mitochondrial localization [2].  We have recently reported 
that our highly potent amphipathic MP analogue mitoparan 
(mitP; [Lys5,8Aib10]MP; Aib = α-aminoisobutyric acid) 
[3,4], specifically promotes apoptosis of human cancer 
cells, as was confirmed by in situ TUNEL staining and 
activation of caspase-3 [4] .  Moreover, we have also 
demonstrated that mitP penetrates plasma membranes and 
redistributes to co-localize with mitochondria [4].  
Complementary studies, using isolated mitochondria, 
further demonstrated that mitP, through co-operation with 
a protein of the permeability transition pore complex 
voltage-dependent anion channel (VDAC), induced 
swelling and permeabilization of mitochondria, leading to 
the release of the apoptogenic factor cytochrome c [4].   
  An expanding field of peptide and cell penetrating 
peptide (CPP) research has focussed on the selective 
targeting of tumours by engineering constructs that 
incorporate cell-specific or tissue–specific address motifs. 
Peptidyl address motifs could enhance the selectivity of 
drug delivery whilst the improved cellular uptake offered 
by CPP enhances bioavailability.  Thus and as a potential 
therapeutic strategy, we extended our findings to design 
target-specific mitP analogues.  The integrin-specific 
address motif RGD and a Fas ligand mimetic WEWT [5] 
were incorporated by N-terminal acylation of mitP to 
produce novel tandem-linked chimeric peptides.  
Results and Discussion 
Design. The ability of MP to form an amphipathic α−helix 
is a major determinant of its biological activity. Lysyl 
residues at positions 4, 11 and 12, together with the amino 
terminus, contribute to a cationic hydrophilic face [6].  In 
accordance with this observation, chimeric mitP analogues 
were rationally designed to maintain the amphipathicity of 
mitP. Z-Gly-RGDf-mitP conferred a cationic charge 
distribution that was compatible with an amphipathic 
α-helix. N- terminal blockade with Z-Gly and the inclusion 
of a D isomer of Phe(f), were additional modifications 
likely to improve the biostability of Z-Gly-RGDf-mitP 
(Table 1). The control peptide Z-Gly-RGEf-mitP was also 
included in this study; since the conservative substitution 
of Glu for Asp in the core RGD sequence prevents integrin 
binding. N-terminal extension of mitP with the Fas ligand 
mimetic peptide WEWT was predicted to be incompatible 
with the formation of an extended amphipathic α-helix. 
Therefore, aminohexanoic acid was used as a flexible 
linker in the chimeric sequence of WEWT(Ahx)mitP.  
 
 
 
 
 
 
 
 
 
Cytotoxicity profiles. MTT conversion was used to 
evaluate the cytotoxic potencies of our chimeric mitP 
analogues.  Table 1 shows LD50 values of all peptides 
tested using ECV304 bladder cancer carcinoma cells. All 
chimeric mitP analogues produced enhanced cytotoxic 
potencies compared to mitP alone and most dramatically 
so with the RGD containing chimeric peptide.  Previous 
reports [2] that advocate MP as a potential anti-tumour 
therapeutic by delivery of the peptide in a target-selective 
cell penetrant liposomal complex, have shown such 
constructs to be effective at concentrations of 25µM.  In 
contrast, we report that mitP is a highly potent 
4.44 + 0.04H-WEWT(Ahx)INLKKLAKL(Aib)KKIL -NH2WEWT(Ahx)mitP
4.71 + 0.05Z-Gly-RGE fINLKKLAKL(Aib)KKIL -NH2Z-Gly-RGE f-mitP
1.40 + 0.13Z-Gly-RGDfINLKKLAKL(Aib)KKIL -NH2Z-Gly-RGDf-mitP
6.81 + 0.05H-INLKK LAKL(Aib)KKIL -NH2MitP
30.26 + 0.05H-INLKALAALAKKIL -NH2MP
LD50
aSequencePeptide
Cytotoxicity was calculated by changes in ECV304 cell 
viability, assessed by MTT conversion. aLD50 values are 
expressed in µM as mean + S.E.M. from 3 separate 
experiments 
Table 1. Mitoparans: sequences and cytotoxic potencies   
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mitochondriotoxic CPP and a structure that easily 
incorporates into a tissue specific construct without 
impacting on the bioactivity of the parent cytotoxin. 
Moreover, the enhanced potency of Z-Gly-RGDf-mitP of 
1.4µM is a concentration readily achievable in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mechanisms. The sequence variant Z-Gly-RGEf-mitP, 
demonstrated a decreased potency to that of 
Z-Gly-RGDf-mitP (Table 1) and suggests that our chimeric 
analogue is indeed binding to integrin receptors.  Further 
investigations were performed to ascertain whether our 
novel-tandem linked chimerae shared the same cell 
penetrant and mitochondriotoxic properties as mitP. Fig. 1 
indicates that following 1 hour, mitP (5µM) assumes a 
distinct co-localization with mitochondrial membranes in 
ECV304 cells.  Similarly, live confocal cell imaging was 
also used to determine the intracellular distribution of our 
chimeric analogues. Fig. 2 clearly shows that 
Z-Gly-RGDf-mitP (5µM) assumes a predominant 
mitochondrial co-localization in ECV304 cells following 1 
hour exposure to the peptide.  Finally and in accordance 
with our previous observations for mitP [4], our chimeric 
analogues induced cell death by apoptotic mechanisms as 
evidenced by in situ TUNEL staining (Fig.3). 
 
We conclude that, our target-selective chimeric mitP 
analogues provide utility for the therapeutic induction of 
apoptosis. 
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Fig. 1. Co-localization of mitP with mitochondria 
 
ECV304 cells were treated with 5µM rhodamine-labelled 
mitP and 200nM Mitotracker Green (Molecular Probes, 
Invitrogen) and viewed by confocal live cell imaging (A). 
Co-localizing pixels are shown here in blue (B) 
Fig. 2. Z-Gly-RGDf-mitP co-localizes with mitochondria 
 
ECV304 cells were treated with 5µM fluorescein-labelled 
Z-Gly-RGDf-mitP and 500nM Mitotracker Deep Red 
(Molecular Probes, Invitrogen) and viewed by confocal live 
cell imaging. 
 
 
Fig. 3. Chimeric mit-P analogues induce apoptosis 
 
Inter-nucleosomal DNA fragmentation, a feature of 
apoptosis was detected by TUNEL in situ cell detection 
assay (Roche). Cells were counterstained with DAPI to 
visualize nuclear DNA. The presence of TMR red 
fluorescence located in the nuclei is indicative of 
apoptosis. 
